Erin E. Wiedmeier-Nutor, M.D., M.P.H.

Open

• A Phase 1, Multicenter, Open-label Study To Evaluate The Safety And Preliminary Efficacy Of Arlocabtagene Autoleucel (BMS-986393) In Novel Combinations In Participants With Relapsed And/or Refractory Multiple Myeloma And Determine The Recommended Dose For Each Add-on Investigational Component Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).